Advertisement
New Zealand markets close in 4 hours 9 minutes

  • NZX 50

    11,884.42
    -62.01 (-0.52%)
     

  • NZD/USD

    0.5965
    +0.0016 (+0.26%)
     

  • NZD/EUR

    0.5558
    +0.0017 (+0.31%)
     

  • ALL ORDS

    7,848.60
    -88.90 (-1.12%)
     

  • ASX 200

    7,588.90
    -94.10 (-1.23%)
     

  • OIL

    83.86
    +0.29 (+0.35%)
     

  • GOLD

    2,341.20
    -1.30 (-0.06%)
     

  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     

  • FTSE

    8,078.86
    +38.48 (+0.48%)
     

  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     

  • DAX

    17,917.28
    -171.42 (-0.95%)
     

  • Hang Seng

    17,284.54
    +83.27 (+0.48%)
     

  • NIKKEI 225

    37,631.18
    +2.70 (+0.01%)
     

  • NZD/JPY

    92.7880
    +0.2920 (+0.32%)
     

Immunocore to present at upcoming investor conferences

Immunocore Holdings Limited
·2-min read
Immunocore Holdings Limited
Immunocore Holdings Limited

Immunocore to present at upcoming investor conferences

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 01 February 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, autoimmune, and infectious diseases, today announced that management will present at the following investor conferences in February:

  • Guggenheim Oncology Conference
    Fireside Chat: Wednesday, February 8, 2023, at 11:20 a.m. ET

ADVERTISEMENT

  • SVB Securities Global Biopharma Conference
    Fireside Chat: Thursday, February 16, 2023, at 2:20 p.m. ET

  • Citi's 2023 Virtual Oncology Leadership Summit
    Fireside Chat: Wednesday, February 22, 2023, at 12:00 p.m. ET

The presentations will be webcast live and will be available in the ‘Investors’ section of Immunocore’s website at www.immunocore.com. A replay of the presentations will be made available for a limited time.

##

About Immunocore

Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune, and infectious disease. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. The Company’s most advanced oncology TCR therapeutic, KIMMTRAK has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.

CONTACT:

Immunocore
Sébastien Desprez, Head of Communications
T: +44 (0) 7458030732
E: sebastien.desprez@immunocore.com
Follow on Twitter: @Immunocore

Consilium Strategic Communications (corporate and financial)
Mary-Jane Elliott/ Chris Welsh/Jessica Hodgson
T: +44 (0)203 709 5700
E: Immunocore@consilium-comms.com

Investor Relations  
Clayton Robertson, Head of Investor Relations
T: +1 215-384-4781
E: ir@immunocore.com